A dose block-randomized, double blinded, placebo controlled, dose-escalation clinical trial to evaluated the safety, tolerability and pharmacokinetics after multiple oral doses of AVI-CO-004 in healthy male subject
Latest Information Update: 18 Sep 2019
At a glance
- Drugs AVI CO 004 (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Avixgen
- 05 May 2017 New trial record